Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases.
Animals
Clinical Trials as Topic
Communicable Diseases, Emerging
/ prevention & control
Disease Models, Animal
Disease Vectors
Drug Evaluation, Preclinical
Female
Humans
Influenza, Human
/ etiology
Pregnancy
Pregnancy Complications, Infectious
/ etiology
Translational Research, Biomedical
Viral Vaccines
/ pharmacology
Virus Diseases
/ prevention & control
Zika Virus Infection
/ etiology
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
08 10 2019
08 10 2019
Historique:
received:
07
05
2019
revised:
22
08
2019
accepted:
23
08
2019
pubmed:
11
9
2019
medline:
26
9
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current "gaps," and prospect what could be done to improve our position. Herein we describe the summit proceedings, "Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases," held October 2-3, 2018, at the Trudeau Institute in Saranac Lake, NY.
Identifiants
pubmed: 31500964
pii: S0264-410X(19)31137-5
doi: 10.1016/j.vaccine.2019.08.061
pmc: PMC7131820
pii:
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Congress
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6248-6254Informations de copyright
Copyright © 2019.
Références
Cell Stem Cell. 2017 Mar 2;20(3):385-396.e3
pubmed: 28041895
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63
pubmed: 27044104
PLoS Negl Trop Dis. 2016 Aug 10;10(8):e0004866
pubmed: 27509037
Vaccine. 2012 Jun 29;30(31):4638-43
pubmed: 22583812
J Virol. 2013 Sep;87(18):10324-33
pubmed: 23864620
J Gen Virol. 2013 Dec;94(Pt 12):2700-2709
pubmed: 24092759
PLoS Pathog. 2018 Apr 10;14(4):e1006994
pubmed: 29634758
Protein Cell. 2017 Nov;8(11):823-833
pubmed: 29058117
Organogenesis. 2014 Apr-Jun;10(2):159-63
pubmed: 24762764
BMJ. 2015 Jul 27;351:h3740
pubmed: 26215666
Nat Immunol. 2018 Jan;19(1):20-28
pubmed: 29199281
Vet Microbiol. 2013 Sep 27;166(1-2):145-53
pubmed: 23834965